Tower Research Capital LLC (Trc) Erasca, Inc. Transaction History
Tower Research Capital LLC (Trc)
- $4.87 Billion
- Q4 2024
A detailed history of Tower Research Capital LLC (Trc) transactions in Erasca, Inc. stock. As of the latest transaction made, Tower Research Capital LLC (Trc) holds 23,323 shares of ERAS stock, worth $34,518. This represents 0.0% of its overall portfolio holdings.
Number of Shares
23,323
Previous 6,776
244.2%
Holding current value
$34,518
Previous $18,000
222.22%
% of portfolio
0.0%
Previous 0.0%
Shares
14 transactions
Others Institutions Holding ERAS
# of Institutions
153Shares Held
227MCall Options Held
10.9KPut Options Held
65.1K-
Frazier Life Sciences Management, L.P. Menlo Park, CA19.4MShares$28.7 Million2.92% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD16.7MShares$24.7 Million0.03% of portfolio
-
Vr Adviser, LLC New York, NY16.2MShares$24 Million6.72% of portfolio
-
Vanguard Group Inc Valley Forge, PA12.7MShares$18.8 Million0.0% of portfolio
-
Logos Global Management LP San Francisco, CA12.5MShares$18.5 Million4.12% of portfolio
About Erasca, Inc.
- Ticker ERAS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 122,147,000
- Market Cap $181M
- Description
- Erasca, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead candidates include ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; ...